Overview
About Retatrutide
Retatrutide (RTA) is a synthetic single-molecule peptide that acts as a triple agonist at the GLP-1, GIP, and glucagon receptors, widely used as a reference compound in metabolic and incretin-pathway research.
It is studied for its combined activity across three incretin and glucagon signalling pathways in preclinical metabolic-research models. Verova supplies Retatrutide strictly as a research-grade reference material. Each batch is manufactured in the United States under strict quality standards, independently tested for purity and potency, and released with its own Certificate of Analysis (COA) tied to a traceable lot number.
Areas of research study
- Incretin (GLP-1 / GIP) receptor signalling research
- Glucagon-receptor pathway studies
- Energy-balance and metabolic-model research
- Comparative triagonist reference studies
The above reflects areas reported in published preclinical literature and is provided for scientific context only. It is not a claim of efficacy, and Retatrutide is not intended to diagnose, treat, cure, or prevent any condition in humans or animals.